Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 3 of 5804
-
New drug cocktail aims to stop triple negative breast cancer from returning
Disease control Not yet recruitingIt is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers in the adjuvant treatment of triple negative breast …
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
Disease control Not yet recruitingThis is a clinical research study for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The study will test a new treatment called "autologous nano CD5-CAR T cells". These are your own immune cells that have been changed in a lab to recog…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a single gene fix a fatal heart condition? a trial aims to find out
⭐️ CURE ⭐️ Recruiting nowThe purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
Phase: PHASE2 • Sponsor: Lexeo Therapeutics • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged donor cells aim to stop leukemia return after transplant
⭐️ CURE ⭐️ Recruiting nowThis is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in…
Phase: PHASE3 • Sponsor: TScan Therapeutics, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Could a simple blood test catch pancreatic cancer before It's too late?
Diagnosis Recruiting nowPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are curr…
Sponsor: Università Vita-Salute San Raffaele • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
3-Day malaria cure could transform treatment
⭐️ CURE ⭐️ Not yet recruitingCurrent treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a …
Phase: PHASE3 • Sponsor: Menzies School of Health Research • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 11:00 UTC
-
Pig kidney trial offers hope to thousands waiting for transplants
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation…
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered vaccine trains immune system to target COVID-19
⭐️ VACCINE ⭐️ Recruiting nowIn December 2019, viral pneumonia caused by a novel beta-coronavirus (Covid-19) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat and prevent se…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:02 UTC
-
New drug could help babies with SMA walk and sit normally
Disease control Recruiting nowIn this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have been diagnosed with SMA through genetic testing but have not yet started showing …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Gene editing trial hopes to fix duchenne muscular dystrophy at its source
Disease control Recruiting nowThe purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55. Given the limitations of existing therapeutic strategies, PBGENE-DMD represents a nov…
Phase: PHASE1, PHASE2 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hope for kids with rare paralysis: gene therapy trial launches
Disease control Recruiting nowPhase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Phase: PHASE3 • Sponsor: Elpida Therapeutics SPC • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can reprogrammed immune cells silence lupus? a small trial aims to find out.
⭐️ CURE ⭐️ ENROLLING_BY_INVITATIONSystemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease. In the treatment of SLE today, glucocorticosteroid hormones, cytost…
Sponsor: N.N. Alexandrov National Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Could a stem cell shot free liver transplant patients from a lifetime of pills?
Disease control Recruiting nowThis clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Radical new schedule aims to cure High-Risk ewing sarcoma
⭐️ CURE ⭐️ Recruiting nowThis single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics a…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 08, 2026 00:00 UTC
-
Gene editing could cure sickle cell and thalassemia in new trial
⭐️ CURE ⭐️ Recruiting nowA promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease. In gene therapy, the investigators introduce new genetic…
Phase: PHASE1 • Sponsor: Daniel Bauer • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
Pig kidney transplant trial offers new hope for kidney patients
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transpl…
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
One-Time gene infusion aims to fight duchenne muscular dystrophy
Disease control Recruiting nowThe study will evaluate the tolerability, safety and efficacy of gene therapy product in boys with Duchenne muscular dystrophy (DMD). In Phase I the participants will be included in two sequential dose cohorts with increasing doses of the investigational product. Based on the res…
Phase: PHASE1, PHASE2 • Sponsor: AO GENERIUM • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a shot for moms shield babies from deadly RSV?
⭐️ VACCINE ⭐️ Recruiting nowRespiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too early and those born with heart and lung problems. It …
Phase: PHASE3 • Sponsor: University of Witwatersrand, South Africa • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:35 UTC
-
Gene-Editing breakthrough aims to stop sickle cell pain
Disease control Recruiting nowThis is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SC…
Phase: PHASE1, PHASE2 • Sponsor: Mark Walters, MD • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Yearly HIV prevention shot could change the game
Prevention OngoingThe goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophy…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC